Integrated Network Pharmacology Analysis and Experimental Validation of Zadi‐5 Against Coronary Heart Disease
Cardiology Research and Practice · 2026-01 · 2026 (1)
DOI: 10.1155/crp/5479556 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiology Research and Practice, online erschienen am 07.07.2026. Verfasst von Jie Xiang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Hygiene and Health Academy, Baotou Medical College, Baotou, China, btmc.cn. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Baotou Medical College.
Abstract (Originalsprache)
This study aimed to investigate the potential molecular mechanisms underlying the therapeutic effects of the traditional Mongolian medicine Zadi‐5 on coronary heart disease (CHD). The active compounds of Zadi‐5 were identified using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, and their corresponding targets were retrieved from HERB. The GSE42148 dataset was used to analyze differentially expressed genes (DEGs) associated with CHD. A compound–target network and a disease–gene–target network were constructed, followed by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses. Molecular docking was performed to predict binding modes. Furthermore, we employed a CHD model with high‐fat diet–fed ApoE −/− mice to explore the protective effects of Zadi‐5 in CHD. A total of 250 targets related to the active compounds in Zadi‐5 were identified. Additionally, 480 DEGs were screened from the GSE42148 dataset, and seven key targets (MPO, IFNG, TOP2A, PTGS2, CYP2J2, F7, and PPARG) were identified. Molecular docking predicted strong binding affinities between PPARG and the main active components of Zadi‐5. Furthermore, Zadi‐5 markedly enhanced the heart performance and reduced fibrotic and inflammatory responses in vivo. Zadi‐5 effectively suppressed the levels of HIF‐1α and increased the PPARG levels in ApoE −/− mice post‐myocardial infarction. These findings suggest that the active components of Zadi‐5 may exert therapeutic effects in CHD by targeting PPARG, as revealed by network pharmacology and molecular docking analyses.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hygiene and Health Academy, Baotou Medical College, Baotou, China, btmc.cn.
ORCID-Profile: Jie Xiang, Jing Liu, Pengmei Liu
Förderung
- Baotou Medical College
Zitieren
APA
Xiang, J., Liu, J., & Liu, P. (2026). Integrated Network Pharmacology Analysis and Experimental Validation of Zadi‐5 Against Coronary Heart Disease. Cardiology Research and Practice, 2026(1). https://doi.org/10.1155/crp/5479556
Vancouver
Xiang J, Liu J, Liu P. Integrated Network Pharmacology Analysis and Experimental Validation of Zadi‐5 Against Coronary Heart Disease. Cardiology Research and Practice. 2026;2026(1). doi:10.1155/crp/5479556
BibTeX
@article{Xiang2026,
author = {Xiang, Jie and Liu, Jing and Liu, Pengmei},
title = {Integrated Network Pharmacology Analysis and Experimental Validation of Zadi‐5 Against Coronary Heart Disease},
journal = {Cardiology Research and Practice},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/crp/5479556}
}
EUVIMED